Investigational therapies for psoriasis

Journal of the American Academy of Dermatology

Volumn 49, Issue 2 A, 2003, Pages 133-138

  Cather, Jennifer Clay ^a,b,c   Cather, John Christian ^a   Abramovits, William ^a,b  

^a Texas Dermatology Associates PA   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; ALEFACEPT; BASILIXIMAB; BEXAROTENE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; DENILEUKIN DIFTITOX; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; IMMUNOMODULATING AGENT; IMUCLONE; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 5; INTERLEUKIN 6; LIAROZOLE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 114; OKT 4; PEPTIDE T; PIMECROLIMUS; PSORAXINE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; REMICAIDE; SIPLIZUMAB; TAZAROTENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ANTIINFLAMMATORY ACTIVITY; APHERESIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; JOINT FUNCTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 0043135083     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(03)01147-2     Document Type: Review

References (48)

1. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis. Arch Dermatol 2002;138:657-63.
2. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLADR, and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000;14:63-78.
3. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB-389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
4. Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 1998;8:938-44.
5. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52.
6. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA41g) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-94.
7. Gottlieb A, Abdulghani A, Totoritis M, Lizambri R, Shuey S, Romano P, et al. Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis. J Invest Dermatol 2000;114:840.
8. Langley R, Roenigk HH, McCall C, Stricklin G, Dingivan C. Phase I results of intravenous MEDI-507, anti-T-cell monoclonal antibody, for the treatment of psoriasis. J Invest Dermatol 2001;117: 817.
9. Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, Hakimi J, Light S, et al. Successful in vivo blockade of CD25 (high-affinity interleulin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000;43:448-58.
10. Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol 2000;25:195-7.
11. Deckert F, Legay F. Development and validation of an immunoreceptor assay for simulect based on surface plasmon resonance. Anal Biochem 1999;274:81-9.
12. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000; 43:595-604.
13. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:264-73.
14. Meingassner JG, Grassberger M, Farngruber H, Moore HD, Schuurmann H, Stuetz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo. Br J Dermatol 1997;137:568-76.
15. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:264-73.
16. Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam dermivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998;290:501-7.
17. Rappersberger K, Komar M, Ebelin M, Scott G, Burtin P, Greig G, et al. Pimerolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002;119:876-7.
18. Reich K, Hilmes D, Middel P, Maurer C, Lippert U, Bruck M, et al. Treatment of psoriasis with IL-10 downregulates the epidermal interleukin-8/CXCR2 pathway. Br J Dermatol 1999;141:980.
19. Asadullah KSW, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998;101:783-94.
20. Nickoloff BJ, Fivenson DP, Kunkel SL, Strieter RM, Turka LA. Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. Clin Immunol Immunopathol 1994;73: 63-8.
21. Trepiccio WL, Ozawa M, Walters IB. IL-11 is an immune-modulatory cytokine which down-regulates IL-12, type 1 cytokines, and multiple inflammation-associated genes in patients with psoriasis. Br J Dermatol 2000;141:976.
22. Asadullah K, Sabat R, Wiese A, Docke WD, Volk HD, Sterry W. Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use. Arch Dermatol Res 1999;291:628-36.
23. Asadullah K, Sterry W, Ebeling M, Friedrich M, Leupold M, Jasulaitis D, et al. Clinicl and immunological effects of IL-10 therapy in psoriasis. Br J Dermatol 1999;141:989.
24. Lohner M, Krueger J, Gottlieb A, Beutner K, Levy R, Wiesenhutter C, et al. Clinical trials of a fully human anti-IL-8 antibody for the treatment of psoriasis. Br J Dermatol 1999;141:989.
25. Asadullah K, Docke WD, Ebeling M, Friedrich M, Belbe G, Audring H, et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 1999;135:187-92.
26. McInnes IB, Illei GG, Danning CL, Yarboro CH, Crane M, Kuroiwa T, et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 2001;167:4075-82.
27. Reich K, Garbe C, Blaschke V, Maurer C, Middel P, Westphal G, et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001;116:319-29.
28. Asadullah K, Friedrich M, Hanneken S, Rohrbach C, Audring H, Vergopoulos A, et al. Effects of systemic interleukin-10 on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J Invest Dermatol 2001;116:721-7.
29. Seifert M, Sterry W, Effenberger E, Rexin A, Friedrich M, Haeussler-Quade A, et al. The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes. Arch Dermatol Res 2000;292:164-72.
30. Friedrich M, Docke WD, Klein A, Philipp S,Volk HD, Sterry W, et al. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J Invest Dermatol 2002;118:672-7.
31. Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999;104:1527-37.
32. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995;105:31-57.
33. Bozza M, Bliss JL, Dorner AJ, Trepicchio WL. Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T cells. J Interferon Cytokine Res 2001;21:21-30.
34. Balagon MV, Tan PL, Prestidge R, Cellona RV, Abalos RM, Tan EV, et al. Improvement in psoriasis after intradermal administration of delipidated, deglycolipidated mycobacterium vaccae (PVAC): results of an open-label trial. Clin Exp Dermatol 2001;26:233-41.
35. Gulliver WP, Adams M, Farrand D, Farber E. Peptide-T: a novel neuro peptide analog for the treatment of psoriasis. Br J Dermatol 1999;141:969-1000.
36. Raychaudhuri SP, Farber EM, Raychaudhuri SK. Immunomodulatory effects of Peptide T on Th1/Th2 cytokines. Int J Immunopharmacol 1999;21:609-15.
37. Talme T, Rozell BL, Sundqvist KG, Wetterberg L, Marcusson JA. Histopathological and immunohistochemical changes in psoriatic skin during Peptide T treatment. Arch Dermatol Res 1995; 287:553-7.
38. Barker NJ, Jones ML, Mitra RS. Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 1991;139:869-76.
39. Biasi D, Carletto A, Caramaschi P. Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis. Inflamm Res 1998;22:533-43.
40. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994;144:820-8.
41. Chandraratna RA. Current research and future developments in retinoids: oral and topical agents. Cutis 1998;61(2 Suppl):40-5.
42. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Staus D, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997;15:790-7.
43. Smit J, de Jong E, van Hooijdonk C, Kooijmans-Otero M, de Jongh G, Lambert J, et al. A multicentre Phase II clinical and immunohistochemical trial of oral bexarotene in patients with moderate to severe plaque psoriasis. J Invest Dermatol 2000; 114:776.
44. Van Pelt JP, de Jong EM, de Bakker ES, van de Kerkhof PC. Effects of systemic treatment with liarozole on cutaneous inflammation, epidermal proliferation and differentiation in extensive plaque psoriasis. Skin Pharmacol Appl Skin Physiol 1998;11:70-9.
45. Dupont E, Savard PE, Jourdain C, Juneau C, Thibodeau A, Ross N, et al. Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg 1998;2:146-52.
46. Lui H. Photodynamic therapy in dermatology with porfimer sodium and benzoporphyrin derivative: an update. Semin Oncol 1994;21(6 Suppl 15):11-4.
47. Boehncke WH, Elshorst-Schmidt T, Kaufmann R. Systemic photodynamic therapy is a safe and effective treatment for psoriasis. Arch Dermatol 2000;136:271-2.
48. Kanekura T, Maruyama I, Kanzaki T. Granulocyte and monocyte absorption apheresis for pyoderma gangrenosum. J Am Acad Dermatol 2002;47:320-21.